91results about How to "Reduce liver toxicity" patented technology

The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.

The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids comprising at least one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.

The present application provides pharmaceutical compositions comprising a population of mononuclear-enriched cells in an early-apoptotic state, methods for the production of said compositions and uses thereof in the treatment of diseases characterized by pathological immune responses. The pharmaceutical compositions may be used in treatment of conditions such as, but not limited to, graft versus host disease (GVHD) and autoimmune diseases including but not limited to inflammatory bowel disease, gout and arthritis.

The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.

The present application provides pharmaceutical compositions comprising a population of mononuclear-enriched cells in an early-apoptotic state, methods for the production of said compositions and uses thereof in the treatment of diseases characterized by pathological immune responses. The pharmaceutical compositions may be used in treatment of conditions such as, but not limited to, graft versus host disease (GVHD) and autoimmune diseases including but not limited to inflammatory bowel disease, gout and arthritis.

The inventive subject matter provides compounds, compositions and methods for lowering serum acid (sUA) for the treatment of gout, and having reduced liver toxicity, associated with CYP2C9 metabolic pathway.

The invention belongs to the medicine field, and relates to tacrine-pyridinothiophene compounds and applications thereof. The saccharides of tacrine-pyridinothiophene compounds have activity on inhibiting kinase-3beta acetyl cholinesterase dual targets. The compounds can be used as a precursor for preventing Alzheimer's disease by inhibiting the activity of cholinesterase.

The instant invention provides for novel cationic lipids of Formula A that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain coupled with inclusion of hydrolysable functionality in the lipid chains to enhance the efficiency and tolerability of in vivo delivery of siRNA.

The invention belongs to the field of medicine research and development, and particularly relates to a compound and application in an anti-tumor medicine thereof. The compound is prepared from a platiniferous anti-tumor compound and a chelating agent, wherein the chelating agent is sodium(S)-2-(dithiocarboxylic acid((2S,3R,4R,5R)-2,3,4,5,6-pentacarbonyl hexyl)amino)-4-(methylmercapto)butyrate. Theinvention further provides application of the compound in the anti-tumor medicine. Through experiment examination, the chelating agent in the compound can effectively chelate heavy metal in the platiniferous anti-tumor compound, so that multiple adverse reaction during exclusive use of the platiniferous compound is effectively reduced, the dosage of the platiniferous anti-tumor compound can be improved, and an anti-tumor effect is optimized; meanwhile, the chelating agent is non-toxic, and has no toxic effects on normal cells; and the technical defects that in the prior art, when the platiniferous anti-tumor compound is used for medication, adverse reaction is large, and medicine resistance is liable to be generated are solved.

A mini-peptide and its analogs have been found to target gene products to tumors. The peptide, named Carcinoma Homing Peptide (CHP), increased the tumor accumulation of the reporter gene products in five independent tumor models, including one human xenogeneic model. A CHP-IL-12 fusion gene was also developed using CHP and the p40 subunit of IL-12. The product from CHP-IL-12 fusion gene therapy increased accumulation of IL-12 in the tumor environment. In three tumor models, CHP-IL-12 gene therapy inhibited distal tumor growth. In a spontaneous lung metastasis model, inhibition of metastatic tumor growth was improved compared to wild-type IL-12 gene therapy, and in a squamous cell carcinoma model, toxic liver lesions were reduced. The receptor for CHP was identified as vimentin. CHP can be used to improve the efficacy and safety of targeted cancer treatments.

The invention belongs to the field of extraction of natural products of plants and in particular relates to a preparation method and application of a macadamia nut leaf extract. The preparation methodcomprises steps of ultrasonic-assisted water extraction and alcohol precipitation, in addition, phenolic acid substances are removed through gel column chromatography, desalting treatment is furtherimplemented, and the macadamia nut leaf extract which is high in polysaccharide content and free of phenolic acid substance is obtained. By adopting the extraction method, conditions can be provided for comprehensive utilization of macadamia nut leaves, and a great amount of leaf resources are not discarded any longer but being adopted to prepare foods or healthcare products with plant polysaccharides.

The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.